

---

## Ascelia Pharma - Just about to submit Orviglance for US approval

Ascelia's two most important value drivers are the US submission, which is now de-risked, and Ascelia is expecting a submission in early September. The second critical value driver is to secure a US partner for the upcoming launch.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Ascelia Pharma - Just about to submit Orviglance for US approval**